Matteo Simonelli

Prof. Matteo Simonelli

Humanitas University
+1
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2017 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
POP. A. Ott
P. A. Ott
SPSarina Anne Piha-Paul
Sarina Anne Piha-Paul
PMP. Munster
P. Munster
MPM. J. Pishvaian
M. J. Pishvaian
EBE. M. J. van Brummelen
E. M. J. van Brummelen
JBJ. Bennouna
J. Bennouna
Safety and efficacy of pembrolizumab, a humanized programmed death 1 monoclonal antibody, was assessed in KEYNOTE-028, a multicohort, phase Ib trial for patients with programmed death ligand 1 (PD-L1)-positive advanced solid tumors. We report results for the cohort of patients with advanced anal carcinoma. Patients with PD-L1-positive tumors (≥1%) received intravenous pembrolizumab 10 mg/kg once every 2 weeks for up to 2 years or until confirmed progression or unacceptable toxicity. Response was assessed every 8 weeks for the first 6 months and every 12 weeks thereafter per Response Evaluation Criteria In Solid Tumors, version 1.1. Primary endpoints were safety and overall response rate per investigator review. Secondary endpoints included progression-free survival, overall survival, and response duration. Data cutoff date was 1 July 2015. Of the 43 patients with advanced anal carcinoma evaluable for PD-L1 expression, 32 (74%) had PD-L1-positive tumors as assessed with the 22C3 prototype assay, of whom 25 were enrolled between April and September 2014. Sixteen patients (64%) experienced treatment-related adverse events; the most common ones were diarrhea and fatigue in four patients (16%) each and nausea in three patients (12%). There were no treatment-related deaths or discontinuations as of the data cutoff date. Among the 24 patients with squamous cell carcinoma histology, four had confirmed partial response, for an overall response rate of 17% [95% confidence interval (CI), 5%–37%) and 10 (42%) had confirmed stable disease, for a disease control rate of 58%. One additional patient with non-squamous histology had confirmed stable disease. In this population of patients with PD-L1-positive advanced squamous cell anal carcinoma, pembrolizumab demonstrated a manageable safety profile and encouraging antitumor activity. These data support further study of pembrolizumab for this patient population. NCT02054806.

8 July 2017 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
FPFederico Pessina
Federico Pessina
Pierina NavarriaPierina Navarria
Pierina Navarria
LCLuca Cozzi
Luca Cozzi
AAAnna Maria Ascolese
Anna Maria Ascolese
MSMatteo Simonelli
Matteo Simonelli
LBLorenzo Bello
Lorenzo Bello

1 February 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PZPaolo Andrea Zucali
Paolo Andrea Zucali
TPTommaso De Pas
Tommaso De Pas
GPGiovannella Palmieri
Giovannella Palmieri
AFAdolfo Favaretto
Adolfo Favaretto
ACAntonio Chella
Antonio Chella
Armando SantoroArmando Santoro
Armando Santoro
Purpose: No effective salvage treatments are available for patients with advanced/recurrent thymoma (T) or thymic carcinoma (TC) who have progressed after platinum-based chemotherapy. This study evaluated the activity of everolimus in patients with advanced/recurrent T or TC previously treated with cisplatin-containing chemotherapy. Patients and Methods: This was a single-arm, single-stage, open-label, multicenter, phase II trial. Patients received oral everolimus 10 mg/d until disease progression, unacceptable toxicity, or patient refusal. A Fleming phase II trial was designed. The null hypothesis of a true disease control rate (DCR) of 40% was tested against a one-sided alternative of a true DCR of 60% (α = β = 0.10): If disease control were achieved in ≥ 21 of the first 41 evaluable patients, everolimus could be recommended for further evaluation. Progression-free survival, overall survival, and safety were also evaluated. Results: From 2011 to 2013, 51 patients were enrolled (T, n = 32; TC, n = 19). Complete remission was observed in one patient with TC, partial response in five patients (T, n = 3; TC, n = 2), and stable disease in 38 patients (T, n = 27; TC, n= 11), with a DCR of 88% (T,: 93.8%; TC, 77.8%). With a median follow up of 25.7 months, median progression-free survival was 10.1 months (T,: 16.6 months; TC, 5.6 months), and median overall survival was 25.7 months (T, not reached; TC, 14.7 months). Fourteen patients had a serious drug-related adverse event; of these patients, nine permanently discontinued treatment. Three patients died of pneumonitis while in the study. Immunohistochemical positivity for p4E-BP1 or insulin-like growth factor-1 receptor was statistically significantly related to a shorter survival. Conclusion: Everolimus may induce durable disease control in a high percentage of patients with T or TC, albeit with a potential high risk of fatal pneumonitis.

26 October 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
MMMatteo Massara
Matteo Massara
PPPasquale Persico
Pasquale Persico
OBOrnella Bonavita
Ornella Bonavita
VPValeria Mollica Poeta
Valeria Mollica Poeta
MLMassimo Locati
Massimo Locati
RBRaffaella Bonecchi
Raffaella Bonecchi
Neutrophils are the most abundant white blood cells and are the first recruited to inflammatory sites. Neutrophils are an important component of the tumor stroma and can exert both antitumoral and protumoral activities, depending on their maturation and activation state. In human gliomas, the number of circulating and infiltrating neutrophils correlates with the severity of the disease, indicating a prognostic and possible pro-tumoral role for these leukocytes. In glioma preclinical models, neutrophils promote tumor growth and orchestrate the resistance to anti-angiogenic therapies. Nevertheless, recent data indicate that neutrophils can be activated to directly kill tumor cells or to orchestrate the antitumoral response. Here, we review current knowledge about the role of neutrophils in glioma and their possible involvement in new strategies to improve current cancer therapies.

26 January 2021 in Cancer
Verified
Journal Article
Closed access
PDF file
DRDavid A. Reardon
David A. Reardon
TKTae Min Kim
Tae Min Kim
JFJean‐Sebastien Frenel
Jean‐Sebastien Frenel
MSMatteo Simonelli
Matteo Simonelli
JLJuanita Lopez
Juanita Lopez
CMChristophe Massard
Christophe Massard

1 April 2011 in Lung Cancer
Verified
Journal Article
Closed access
GCGiovanni L. Ceresoli
Giovanni L. Ceresoli
PZPaolo A. Zucali
Paolo A. Zucali
FVFabio De Vincenzo
Fabio De Vincenzo
LGLetizia Gianoncelli
Letizia Gianoncelli
MSMatteo Simonelli
Matteo Simonelli
ASArmando Santoro
Armando Santoro